The Revolt and The Revolting: May 18, 2020

Monday, May 18, 2020

Fever might not be the most common coronavirus symptom

The smell sense of the brain is very near the face and eyes. The article mentioned below doesn't discount fever is a symptom but the one characteristic that sets the SARS-CoV-2 apart from others is it's brain involvement.

After receiving smell information from the nose’s sensory receptors, the olfactory bulb relays the information to a circuit of brain regions for processing.

May 18, 2020

Now, a study from the Harvard-affiliated Cambridge Health Alliance (click here) that was published in Mayo Clinic Proceedings has examined 1,000 records from outpatients. The researchers were looking for differences between COVID-19 and other diseases that have similar common symptoms. What they found was that shortness of breath for COVID-19 patients gradually becomes worse over a few days, and that fever is not "a reliable indicator" for infection. The study also found that the disease can just start with coughing and no other symptoms at all....

...On top of that research, doctors from Europe examined 1,420 patients from 18 different hospitals, and what they found was that fever was only present in 45% of cases. The most common symptom out of all the patients was headaches at 70.3%, followed closely by a loss of smell at 70.2%....

The per capita income is $7,269.00.

The pointer in the upper right-hand corner is pointing north with the Navajo Nation overlaying it.

...Health care on the Navajo Nation (click here) is provided by many different public health systems that strive to work together, but which have no common oversight. Few understand what services are available across state lines on the reservation or how to access those services, especially as the state systems keep modernizing and changing. However, a comprehensive understanding of these interlinked systems is necessary in order to really assist tribal members....

May 18, 2020
By Hollie Silverman, Konstantin Toropin, Sara Sidner and Leslie Perrot

The Navajo Nation (click here) has surpassed New York and New Jersey for the highest per-capita coronavirus infection rate in the US -- another sign of Covid-19's disproportionate impact on minority communities.

The Navajo Nation, which spans parts of Arizona, New Mexico and Utah, reported a population of 173,667 on the 2010 census. As a result, with 4,002 cases, the Native American territory has 2,304.41 cases of Covid-19 per 100,000 people.

By contrast, New York state now has a rate of 1,806 cases per 100,000 and New Jersey is at 1,668 cases per 100,000, according to data from Johns Hopkins University.

Navajo Nation President Jonathan Nez told CNN's Sara Sidner of its rate on the "Situation Room" Sunday night....

It is unclear how much PPE and ventilators they have at their health care facilities.

Hospitals: (click here)

The Navajo Area Indian Health Service (IHS) maintains 5 hospitals in "service units": Chinle Comprehensive Health Care Facility, Crownpoint Health Care Facility, Gallup Indian Medical Center, and Northern Navajo Medical Center (Shiprock, NM), totalling 222 hospital beds; and the Kayenta Health Center in Kayenta, AZ, an Alternative Rural Hospital with 10 short stay nursing beds and ambulatory surgery....

Israel is linked to a cyberattack on Iranian shipping.

There was an attack against Iranian backed fighters. The attack took place in East Syria. A retiring Israeli general stated Iran is withdrawing from Syria. The seven dead were Iraqi militiamen. It was in the Iraq-Syrian border.

Where is Deash these days?

The dead fighters were brought to the border as reinforcements. Iraq needs to protect its borders and it is widely understood that Iraqi militias are vital to such operations by Iraq. There is a human rights group observing the region.

A One-Off for the EU.

May 18, 2020

Faced with economic recession and deep strains in the European Union over the coronavirus, German Chancellor Angela Merkel on Monday agreed to what would amount to collective European debt to help those countries hit hardest by the pandemic.

Ms. Merkel joined with the French president, Emmanuel Macron, to propose a 500 billion euro ($545 billion) recovery fund, financed by the European Union and repaid through the collective Brussels budget, to help European regions and economic sectors battered by the coronavirus.

The proposal must be agreed to by the other 25 member states of the bloc, some of which have also rejected collective indebtedness in the past....

Their parental rights should be in question.

Children have horrific symptoms from SARS-CoV-2. It is a fact that has been identified by the CDC. Any parent willing to expose their children, regardless of age, to any level of exposure is too dangerous to maintain their parental rights.

May 18, 2020
By Gregory Pratt

Pastor Joseph Wyrostek, 43, holds his 1-year-old son Titus while standing next to his wife Nancy and their daughters Bethany, 11, Joy, 3, and Hannah, 10, during a service at the Metro Praise International Church on Sunday.

The city (click here) will be fining churches that had more people than allowed under the statewide stay-at-home order, Chicago Mayor Lori Lightfoot said Monday.

Which ones specifically will be determined later today, Lightfoot said.

Over the past week, Lightfoot had been asking churches to abide by social distancing rules and warning that she would take action against churches that refused.

But on Sunday, hundreds of people defied Illinois Gov. J.B. Pritzker’s stay-at-home order to attend church anyway and the mayor’s office warned that violators may be cited after review....

Donald John Trump has a mental health problem.

Hydroxychloroquine (click here) is a very dangerous drug, ESPECIALLY over the long term.

I would never take that drug on a permanent basis. Trump is taking it because he is terrified of SARS-CoV-2.

Does he take bleach every morning in his morning juice?

Whoever prescribed it to him needs to be on review for the efficacy of a medical license.

Moderna has their own manufacturing facility, however, if their vaccine is successful the company will need to expand or contract additional manufacturing.

Go, Moderna, Go!

Moderna (click here)
Celebrating a Year of Progress at Norwood
July 17, 2019

By Juan Andres
Chief Technical Operations and Quality Officer and the Norwood Leadership Team

Happy anniversary to our Moderna team at Norwood! One year ago, we opened our digitally-enabled and environmentally-sustainable 200,000 square foot clinical development manufacturing plant in Norwood, Massachusetts, to help advance Moderna’s pipeline of mRNA-based medicines....

May 18, 2020
By Carmen Reinicke

"Moderna" is soaring (click here) after an early trial of its coronavirus vaccine produced positive results, the company announced Monday.

Shares of the pharmaceutical company surged as much as 39% in premarket trading Monday in New York after it announced that all 45 volunteers in a trial for its coronavirus vaccine produced antibodies that may help protect them against the disease.

The phase 1 trial was conducted by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health....

More details.

May 18, 2020

Cambridge - Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology (click here) company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg dose levels. All participants ages 18-55 (n=15 per cohort) across all three dose levels seroconverted by day 15 after a single dose. At day 43, two weeks following the second dose, at the 25 µg dose level (n=15), levels of binding antibodies were at the levels seen in convalescent sera (blood samples from people who have recovered from COVID-19) tested in the same assay. At day 43, at the 100 µg dose level (n=10), levels of binding antibodies significantly exceeded the levels seen in convalescent sera. Samples are not yet available for remaining participants....

News from Massachusetts

May 18, 2020
By Carmen Reinicke

"Moderna" is soaring (click here) after an early trial of its coronavirus vaccine produced positive results, the company announced Monday.

Shares of the pharmaceutical company surged as much as 39% in premarket trading Monday in New York after it announced that all 45 volunteers in a trial for its coronavirus vaccine produced antibodies that may help protect them against the disease.

The phase 1 trial was conducted by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health....

More details.

May 18, 2020

Cambridge - Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology (click here) company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg dose levels. All participants ages 18-55 (n=15 per cohort) across all three dose levels seroconverted by day 15 after a single dose. At day 43, two weeks following the second dose, at the 25 µg dose level (n=15), levels of binding antibodies were at the levels seen in convalescent sera (blood samples from people who have recovered from COVID-19) tested in the same assay. At day 43, at the 100 µg dose level (n=10), levels of binding antibodies significantly exceeded the levels seen in convalescent sera. Samples are not yet available for remaining participants....

"Morning Papers"

The Rooster

Okeydoke

There is every indication the US Postal Service will have to be provided vigilance for changes in regulations that will dismantle election ballots for the upcoming 2020 election in November.

California has already decided to issue mail-in ballots to all it's citizens for elections. Someone in the State Attorney General's Office will have to monitor changes that are adverse to the electorate and elections. It is normally the Secretary of State that is responsible for election integrity, however, an assistant from the AG's office will allow the Secretary to move directly to court should there be adverse regulations instituted. The adverse regulations are expected to occur as Trump has completely corrupted the Post Master General's office and the Board of Governors.

I am quite certain A RIGHT TO SIT IN ON THE MEETINGS of the Board of Governors will be important to intercede as quickly as possible.

7-7.1 Federal Laws Applicable to the Postal Service (click here)

"Good Night, Moon"

The waning crescent

25.3 day old moon

18.7 percent lit

The USA has ordered 18 engines for moon missions. No one talks about any of this. Four engines are used for liftoff.

The RS-25 is half of the powerful, (click here) proven SLS propulsion systems designed to launch humans and large exploration payloads to the Moon and ultimately to Mars and beyond. Four RS-25 engines, along with two 5-segment solid rocket boosters, will give SLS approximately 8.8 million pounds of thrust during launch – more lift than any current launch vehicle and 15 percent more than the Saturn V rockets that launched astronauts on journeys to the moon.

With unmatched payload mass and volume capability, the advanced, super heavy-lift SLS is the only rocket that can send the Orion spacecraft, astronauts, and a large cargo to the Moon on a single mission. This reduces the number and complexity of in-space operations and increases the chances of mission success....

The first Artemis rocket stage (click here) is guided toward NASA’s Pegasus barge Jan. 8 ahead of its forthcoming journey to NASA’s Stennis Space Center near Bay St. Louis, Mississippi. Teams rolled out, or moved, the completed core stage for NASA’s Space Launch System (SLS) rocket from NASA’s Michoud Assembly Facility in New Orleans to the barge in preparation for the core stage Green Run test series. Pegasus, which was modified to ferry SLS rocket hardware, will transport the core stage more than 40 miles from Michoud to Stennis for the comprehensive core stage Green Run test series. Green Run, named for its testing of new, or green, hardware progressively, is the final test campaign ahead of the first Artemis launch.